Healthcare spending in the United States is the highest in the world: totaling $3.3 trillion—or 17.8% of the GDP—in 2016. To capture market share—and to expand the market—drug companies and healthcare organizations ...
Jan 8, 2019
2
15
Thirty years ago, scientists began to unlock the mysteries regarding the cause of Alzheimer's disease. This knowledge ushered in an era of great enthusiasm that scientists could develop new therapies to either prevent Alzheimer's ...
Nov 16, 2017
0
58
The rising price for EpiPens, a drug delivery system that is crucial for persons experiencing potentially life-threatening allergic reactions, has resulted in outrage. The price increase, from about US$94 for a two-pack of ...
Aug 25, 2016
0
1
From Cameroon to Ivory Coast, Kenya to the DR Congo, traders in counterfeit drugs do a thriving business with the utmost cynicism and sometimes at the cost of human lives.
Aug 22, 2013
0
0
(HealthDay)—Social and population variations in mental diagnosis are not accounted for in the newly revised fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), according to an editorial published ...
May 14, 2013
1
0
The new feature of the antidepressant drugs of the 1990s was that they had milder side-effects than their predecessors. Combined with aggressive marketing, this meant that annual sales in Sweden increased from just under ...
May 2, 2013
0
0
The India Supreme Court's rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world's largest drugmakers.
Apr 1, 2013
0
0
(HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, ...
Feb 7, 2013
0
0
They say the real crisis stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones.
Aug 7, 2012
0
0
Conflict-of-interest statements made by physicians and scientists in their medical journal articles after they had been allegedly paid by pharmaceutical manufacturers as part of off-label marketing programs are often inadequate, ...
Aug 7, 2012
0
0
